Zydus Healthcare gets CDSCO panel nod to study Dydrogesterone film coated Sustained Release Tablets

Published On 2023-02-17 12:30 GMT | Update On 2023-02-17 12:30 GMT

New Delhi: Suggesting to monitor the size of endometrioma during the study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has given its nod to drug major Zydus Healthcare for phase III clinical trial to assess the efficacy and safety of Dydrogesterone film coated sustained release tablets 20 mg as compared to Dydrogesterone tablets 10mg for the treatment of endometriosis in women.

This came after the firm represented the Phase III clinical trial protocol BIOS/2022/267, version No. 01 dated 06.10.2022.

Regarding the study, the firm added, “Prospective, randomized, double-blind study, single dummy, two-arm, active-controlled, parallel, multicentre, Phase III clinical trial to assess the efficacy and safety of Dydrogesterone film coated sustained release tablets 20 mg as compared to Dydrogesterone tablets 10mg for the treatment of endometriosis in women.”

Endometriosis is a disease characterized by the presence of tissue resembling endometrium (the lining of the uterus) outside the uterus. It causes a chronic inflammatory reaction that may result in the formation of scar tissue (adhesions, fibrosis) within the pelvis and other parts of the body.

Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions. Dydrogesterone is a progestogen that works by regulating the healthy growth and normal shedding of the womb lining by acting on progesterone receptors in the uterus

At the recent SEC meeting for Reproductive & Urology held on 31st January 2023, the expert panel reviewed the Phase III clinical trial protocol BIOS/2022/267, version No. 01 dated 06.10.2022.

After detailed deliberation, the committee recommended the grant of permission to conduct the clinical trial. The committee also suggested to monitor the size of endometrioma during the study.

Also Read:Eli Lilly gets CDSCO panel nod to study anticancer drug Imlunestrant

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Healthcare gets CDSCO panel nod to study Dydrogesterone film coated Sustained Release Tablets

Similar News

Sun Pharma Agrees To Rs 1,654 Cr Settlement In U.S. Pricing Row

No Special Price for Novel Pack: NPPA Panel Turns Down Sun Pharma's Amoxicillin-Clavulanic Formulation

CDSCO Panel Seeks Safety Data on 5% Lenalidomide TDS Before Clearing 8% Patch Trial

Dr Reddy's Labs plans to roll out cheaper Wegovy copycat across 87 countries in 2026: CEO

Action taken against 694 manufacturing units since 2022: Minister

J&J Imbruvica gains EU approval for untreated Mantle Cell Lymphoma in transplant eligible patients

Shilpa Medicare arm to infuse USD 2 million in Alveolus Bio

NPPA Panel Rejects Dr Reddy's Omez ODT Plea For Seperate Price, Finds No Therapeutic Edge